Information is solely for medical professionals
Beifuji Lyophilized Powder
Bovine Basic Fibroblast Growth Factor Lyophilized Powder
/
Specification 35000IU/bottle. The volume is 8ml after dissolving in injection water
Beifuji Lyophilized Powder is a national  category I new drug developed and manufactured by Zhuhai Essex Bio-Pharmaceutical Co.,Ltd..

The API of  Beifuji Lyophilized Powder is recombinant bovine basic fibroblast growth factor (rb-bFGF) – a multifunctional growth factor with a wide range of bioactivities, which can stimulate the proliferation and differentiation of cells in the process of wound healing and further improve the healing quality.
Mechanism
The API of Beifuji is recombinant bovine basic fibroblast growth factor (rb-bFGF), which can stimulate the reparation and regeneration of tissues and cells derived from the mesoderm and ectoderm (such as epithelial cells, dermal cells, fibroblasts, vascular endothelial cells, osteoblasts, nerve cells etc.). The specific combination of rb-bFGF with the wounded target cell surface can trigger the cells to repair actively and stimulate cell division, proliferation, migration and differentiation, so as to accelerate wound healing and improve the healing quality.
Features
· Dripping bottle design - easy to use
· Accelerate wound healing
· Shortening the healing time and reduce scar formation
· Aseptic preparation on site – higher activity of the active ingredient
· Work directly on the repairtive cells accelerating wound healing
· Safe and effective treatment without any side effect
Clinical Application
· Burn and scald wounds: including shallow II degree and deep II degree wounds, granulation wounds and inhalation injuries
· Acute wounds: bruises, contusions, combined injuries and cuts
· Surgical incisions: incisions of surgery, orthopedics, gynaecology (such as lateral episiotomy and cesarean incision), otolaryngology, urology and proctology
· Chronic wounds: diabetic ulcers, vascular ulcers, radiochemotherapy ulcers, bedsores, fistulas, residual wounds and cervical erosions
· Skin grafting: skin donor site, skin grafting site, skin flap handling
· Other applications: after plastic surgery, skin resurfacing, dermabrasion, nevus removal and laser therapy wounds
NDRL
《National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (2019)》
Medical Guidelines
· Chinese Dermatologist Consensus about Application of Recombinant Bovine BasicFibroblast Growth Factor (rb-bFGF) for Laser and IPLS Treatment and Skin Barrier Repairment (2019)
· Clinical Guidelines for Use of Exogenous Growth Factors in Skin Wounds, Chin J Burns (2017)
· Expert Advice on Diagnosis and Treatment of Pemphigus Vulgaris (2016)
· Chinese Guidelines for Diagnosis and Treatment of Skin Wounds (2015)
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.